This announcement is a separate document:
复旦张江自愿披露关于注射用FZ-AD005抗体偶联剂用于治疗晚期实体瘤Ⅰ期临床试验完成首例受试者入组的公告
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. Ltd voluntarily disclosed the announcement of completing the first subject enrollment in Phase I clinical trial for injection of FZ-AD005 antibody conjugate for the treatment of advanced solid tumors.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.